Document Classification

Section Type: RESULTS

Text: Significantly greater (P < 0. 0001) reductions in A1C from a mean + / - SD baseline of 7. 9 + / - 0. 7 % were observed in all taspoglutide groups compared with placebo after 8 weeks of treatment : -1. 0 + / - 0. 1 % (5 mg once weekly), -1. 2 + / - 0. 1 % (10 mg once weekly), -1. 2 + / - 0. 1 % (20 mg once weekly), -0. 9 + / - 0. 1 % (10 mg Q2W), and -1. 0 + / - 0. 1 % (20 mg Q2W) vs. -0. 2 + / - 0. 1 % with placebo.